Ranking Invest

Xenon Pharmaceuticals Inc.

Segmento: Healthcare Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Indicadores Básicos

Valor de Mercado

$ 2.88 Bi

IVR

0.03

IVR2

-0.22

Índices de Previsibilidade

Faturamento

1.42

Lucro

0.10

Margem

1.37

Índices de Tendência

Faturamento

-3.15

Lucro

-11.54

Margem

2.22

Índices de Endividamento

DIV/PAT

-0.15

DIV/L4T

0.43

Dívida Líquida

-$ 107.98 Mi

Patrimônio Líquido

$ 703.96 Mi

L4T

-$ 251.45 Mi

MM4T

-216.82%

Dívidas
Dividendos
Cotação: $37.36

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre